Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
Erasmus School of Health Policy & Management and Erasmus Choice Modelling Centre, Erasmus University, Rotterdam, Netherlands.
Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.ORCID iD: 0000-0002-5865-5590
Show others and affiliations
2019 (English)In: Frontiers in Pharmacology, ISSN 1663-9812, E-ISSN 1663-9812, Vol. 10, article id 1009Article in journal (Refereed) Published
Abstract [en]

Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) bodies/payers for use in assessments and decision-making along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the value of patient preference studies (PPS) in decision-making along the MPLC according to different stakeholders.

Methods: Semi-structured interviews (n = 143) were conducted with six different stakeholder groups (physicians, academics, industry representatives, regulators, HTA/payer representatives, and a combined group of patients, caregivers, and patient representatives) from seven European countries (the United Kingdom, Sweden, Italy, Romania, Germany, France, and the Netherlands) and the United States. Framework analysis was performed using NVivo 11 software.

Results: Fifteen factors affecting the value of PPS in the MPLC were identified. These are related to: study organization (expertise, financial resources, study duration, ethics and good practices, patient centeredness), study design (examining patient and/or other preferences, ensuring representativeness, matching method to research question, matching method to MPLC stage, validity and reliability, cognitive burden, patient education, attribute development), and study conduct (patients’ ability/willingness to participate and preference heterogeneity). Three types of situations affecting the use of PPS results were identified (stakeholder acceptance, market situations, and clinical situations).

Conclusion: The factors and situation types affecting the value of PPS, as identified in this study, need to be considered when designing and conducting PPS in order to promote the integration of PPI into decision-making along the MPLC.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2019. Vol. 10, article id 1009
Keywords [en]
patient preferences, drug life cycle, decision-making, health technology assessment, benefit risk assessment, market authorization
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:uu:diva-393365DOI: 10.3389/fphar.2019.01009ISI: 000486438000001PubMedID: 31619989OAI: oai:DiVA.org:uu-393365DiVA, id: diva2:1352851
Projects
IMI-PREFER
Funder
EU, Horizon 2020Available from: 2019-09-20 Created: 2019-09-20 Last updated: 2019-10-31Bibliographically approved

Open Access in DiVA

fulltext(1439 kB)46 downloads
File information
File name FULLTEXT01.pdfFile size 1439 kBChecksum SHA-512
18178ee9b7cc4ba26f9be0c21874e677781a44fac504949c88ec32045e201422e5cadeced956dbc51557bb2d4ad3f58cd8ca03f17e3aeb9b7a6cdff60289078e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Schölin Bywall, Karin
By organisation
Centre for Research Ethics and Bioethics
In the same journal
Frontiers in Pharmacology
Social and Clinical Pharmacy

Search outside of DiVA

GoogleGoogle Scholar
Total: 46 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 24 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf